Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doron Almagor

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 31, 2025
Managing comorbid sleep issues in patients with attention-deficit/hyperactivity disorderAyan Dey, Thuy Linh Do, Doron Almagor, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 2, 2025
Ayan Dey, Thuy Linh Do, Doron Almagor, et al.
Clinical Therapeutics|October 10, 2017
Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting DatabasesLaura Park-Wyllie, Judy van Stralen, Genaro Castillon, et al.
Clinical Therapeutics|August 2, 2016
Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort StudyLaura Park-Wyllie, Judy Van Stralen, Doron Almagor, et al.
Human Psychopharmacology|September 10, 2013
The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorderRoger S McIntyre, Mohammad Alsuwaidan, Joanna K Soczynska, et al.
Neuroscience and Biobehavioral Reviews|February 7, 2021
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorderStephen V Faraone, Tobias Banaschewski, David Coghill, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 31, 2025
Managing comorbid sleep issues in patients with attention-deficit/hyperactivity disorderAyan Dey, Thuy Linh Do, Doron Almagor, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 2, 2025
Ayan Dey, Thuy Linh Do, Doron Almagor, et al.
Clinical Therapeutics|October 10, 2017
Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting DatabasesLaura Park-Wyllie, Judy van Stralen, Genaro Castillon, et al.
Clinical Therapeutics|August 2, 2016
Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort StudyLaura Park-Wyllie, Judy Van Stralen, Doron Almagor, et al.
Human Psychopharmacology|September 10, 2013
The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorderRoger S McIntyre, Mohammad Alsuwaidan, Joanna K Soczynska, et al.
Neuroscience and Biobehavioral Reviews|February 7, 2021
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorderStephen V Faraone, Tobias Banaschewski, David Coghill, et al.
Pageof 1